NCT04234022View on ClinicalTrials.gov

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

RecruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Zn-DDC

Zn-DDC added to myeloma samples for culturing

DRUG

Lanalidomide with Zn-DDC

Lanalidomide with Zn-DDC added to myeloma samples for culturing

DRUG

Pomalidomide with Zn-DDC

Lanalidomide with Zn-DDC added to myeloma samples for culturing

Trial Locations (1)

WV10 0QP

RECRUITING

The Royal Wolverhampton NHS Trust, Wolverhampton

All Listed Sponsors
collaborator

University of Wolverhampton

OTHER

lead

The Royal Wolverhampton Hospitals NHS Trust

OTHER_GOV